Medical devices, healthcare technology and the business of care
PMA approval · P140029

Restylane Refyne, Restylane Defyne

Q-Med AB · Decision date Dec 9, 2016

MEDTECHLEDGER EXPLANATIONP140029

What did the FDA approve?

The FDA database entry for P140029 records a December 9, 2016 approval for two dermal implants from Q-Med AB. Restylane Refyne is approved for injection into the mid-to-deep dermis to correct moderate to severe facial wrinkles and folds, such as nasolabial folds, in patients over 21. Restylane Defyne carries the same age and injection-depth language but is limited to moderate to severe, deep facial wrinkles and folds.

This entry is an original PMA approval, not a supplement or manufacturing notice. The statement reports the approved indications only; it does not provide independent evidence of safety or clinical effectiveness. No trial data, performance metrics, or comparative outcomes appear in the source fields.

FDA approval order statement

Approval for Restylane Refyne is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. Restylane Defyne is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe, deep facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Dec 9, 2016

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140029
Regulatory pathway
Premarket approval application
Applicant
Q-Med AB
Product code
LMH
Decision code
APPR
Decision date
Dec 9, 2016
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Q-Med AB
Product code
LMH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P140029 received

    Application receipt date recorded by FDA.

  2. P140029 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P140029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140029

Product / regulatory recordCompanyPathwayDecision dateSource
Restylane ContourP140029/S058
Q-Med ABPMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Q-Med AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seminariegatan 21, Uppsala, S-752 28

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records